KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Debt (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 16 years of Non-Current Debt data on record, last reported at $51.9 million in Q4 2024.

  • For Q4 2024, Non-Current Debt rose 24.11% year-over-year to $51.9 million; the TTM value through Dec 2024 reached $51.9 million, up 24.11%, while the annual FY2024 figure was $51.9 million, 24.11% up from the prior year.
  • Non-Current Debt reached $51.9 million in Q4 2024 per IONS's latest filing, up from $41.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $60.0 million in Q2 2021 and bottomed at $8.8 million in Q1 2023.
  • Average Non-Current Debt over 5 years is $38.7 million, with a median of $41.8 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: tumbled 74.87% in 2020, then surged 298.87% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $60.0 million in 2020, then decreased by 0.45% to $59.7 million in 2021, then crashed by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then increased by 24.11% to $51.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $51.9 million in Q4 2024, $41.8 million in Q4 2023, and $8.8 million in Q1 2023.